SCHEMBL6497186

SCHEMBL6497186

O=C(Nc1ccc(NCCc2ccccn2)cc1)c1cc(F)ccc1-c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.53
KDM4E B2RXH2 4/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GCGR P47871 4/20 0.47
GAA P10253 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTT P42858 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.45
CTNNB1 P35222 1/20 0.44
TCF7L2 Q9NQB0 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
NR3C1 P04150 1/20 0.44
GRM4 Q14833 1/20 0.43
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490335 0.95 CNR1 (0.52) CNR1KDM4EHPGDSMN1; SMN2GCGR
SCHEMBL6487583 0.94 HTT (0.52) CNR1KDM4EGCGRGAAMEN1
SCHEMBL6488474 0.94 CNR1 (0.57) CNR1KDM4EHPGDSMN1; SMN2GCGR
SCHEMBL6502209 0.90 CTNNB1 (0.50) KDM4ESMN1; SMN2GAAMEN1KMT2A
SCHEMBL7085345 0.90 CNR1 (0.55) CNR1KDM4EHPGDSMN1; SMN2GCGR
SCHEMBL6499473 0.90 CTNNB1 (0.53) CNR1KDM4EHPGDSMN1; SMN2GCGR
SCHEMBL6793707 0.89 CNR1 (0.58) CNR1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL6491719 0.89 SMO (0.53) KDM4EGCGRGAAMEN1KMT2A
SCHEMBL6488828 0.89 CNR1 (0.51) CNR1KDM4EHPGDSMN1; SMN2GCGR
SCHEMBL6497806 0.88 CNR1 (0.57) CNR1KDM4EHPGDSMN1; SMN2GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 CNR1 102/4885KDM4E 2286/4885HPGD 2564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.